APA (7th ed.) Citation

MT, J., MD, J., F, G., LJ, N., JY, S., Y, L., . . . FL, L. (2022). Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clinical lymphoma, myeloma & leukemia, 22(10), 753. https://doi.org/10.1016/j.clml.2022.05.004

Chicago Style (17th ed.) Citation

MT, Jacobs, et al. "Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium." Clinical Lymphoma, Myeloma & Leukemia 22, no. 10 (2022): 753. https://doi.org/10.1016/j.clml.2022.05.004.

MLA (9th ed.) Citation

MT, Jacobs, et al. "Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium." Clinical Lymphoma, Myeloma & Leukemia, vol. 22, no. 10, 2022, p. 753, https://doi.org/10.1016/j.clml.2022.05.004.